Literature DB >> 29348545

Motor neuron disease in 2017: Progress towards therapy in motor neuron disease.

Matthew C Kiernan1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29348545     DOI: 10.1038/nrneurol.2017.186

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

Review 1.  Cortical influences drive amyotrophic lateral sclerosis.

Authors:  Andrew Eisen; Heiko Braak; Kelly Del Tredici; Roger Lemon; Albert C Ludolph; Matthew C Kiernan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-07-14       Impact factor: 10.154

2.  Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Authors:  Vincent Meininger; Angela Genge; Leonard H van den Berg; Wim Robberecht; Albert Ludolph; Adriano Chio; Seung H Kim; P Nigel Leigh; Matthew C Kiernan; Jeremy M Shefner; Claude Desnuelle; Karen E Morrison; Susanne Petri; Diane Boswell; Jane Temple; Rajat Mohindra; Matt Davies; Jonathan Bullman; Paul Rees; Arseniy Lavrov
Journal:  Lancet Neurol       Date:  2017-01-28       Impact factor: 44.182

3.  Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.

Authors: 
Journal:  Lancet Neurol       Date:  2017-05-15       Impact factor: 44.182

4.  Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Authors:  Richard S Finkel; Eugenio Mercuri; Basil T Darras; Anne M Connolly; Nancy L Kuntz; Janbernd Kirschner; Claudia A Chiriboga; Kayoko Saito; Laurent Servais; Eduardo Tizzano; Haluk Topaloglu; Már Tulinius; Jacqueline Montes; Allan M Glanzman; Kathie Bishop; Z John Zhong; Sarah Gheuens; C Frank Bennett; Eugene Schneider; Wildon Farwell; Darryl C De Vivo
Journal:  N Engl J Med       Date:  2017-11-02       Impact factor: 91.245

5.  The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder.

Authors:  Martin R Turner; Matthew C Kiernan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-12-30       Impact factor: 10.154

Review 6.  Amyotrophic lateral sclerosis.

Authors:  Matthew C Kiernan; Steve Vucic; Benjamin C Cheah; Martin R Turner; Andrew Eisen; Orla Hardiman; James R Burrell; Margaret C Zoing
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

7.  Genetic correlation between amyotrophic lateral sclerosis and schizophrenia.

Authors:  Russell L McLaughlin; Dick Schijven; Wouter van Rheenen; Kristel R van Eijk; Margaret O'Brien; René S Kahn; Roel A Ophoff; An Goris; Daniel G Bradley; Ammar Al-Chalabi; Leonard H van den Berg; Jurjen J Luykx; Orla Hardiman; Jan H Veldink
Journal:  Nat Commun       Date:  2017-03-21       Impact factor: 14.919

8.  Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.

Authors:  Ruben P A van Eijk; Marinus J C Eijkemans; Toby A Ferguson; Stavros Nikolakopoulos; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-30       Impact factor: 10.154

Review 9.  Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.

Authors:  Ruben P A van Eijk; Ashley R Jones; William Sproviero; Aleksey Shatunov; Pamela J Shaw; P Nigel Leigh; Carolyn A Young; Christopher E Shaw; Gabriele Mora; Jessica Mandrioli; Giuseppe Borghero; Paolo Volanti; Frank P Diekstra; Wouter van Rheenen; Esther Verstraete; Marinus J C Eijkemans; Jan H Veldink; Adriano Chio; Ammar Al-Chalabi; Leonard H van den Berg; Michael A van Es
Journal:  Neurology       Date:  2017-10-04       Impact factor: 11.800

  9 in total
  6 in total

1.  Interaction of Half Oxa-/Half cis-Platin Complex with Human Superoxide Dismutase and Induced Reduction of Neurotoxicity.

Authors:  Francesca Cantini; Vito Calderone; Lorenzo Di Cesare Mannelli; Magdalena Korsak; Leonardo Gonnelli; Oscar Francesconi; Carla Ghelardini; Lucia Banci; Cristina Nativi
Journal:  ACS Med Chem Lett       Date:  2018-10-01       Impact factor: 4.345

2.  Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS.

Authors:  Emiliano Trias; Peter H King; Ying Si; Yuri Kwon; Valentina Varela; Sofía Ibarburu; Mariángeles Kovacs; Ivan C Moura; Joseph S Beckman; Olivier Hermine; Luis Barbeito
Journal:  JCI Insight       Date:  2018-10-04

3.  Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis.

Authors:  Joseph B Sweeney; Marcus Rattray; Victoria Pugh; Lucy A Powell
Journal:  ACS Med Chem Lett       Date:  2018-05-30       Impact factor: 4.345

4.  Geographic Analysis of Motor Neuron Disease Mortality and Heavy Metals Released to Rivers in Spain.

Authors:  Germán Sánchez-Díaz; Francisco Escobar; Hannah Badland; Greta Arias-Merino; Manuel Posada de la Paz; Verónica Alonso-Ferreira
Journal:  Int J Environ Res Public Health       Date:  2018-11-11       Impact factor: 3.390

5.  Microhexagon gradient array directs spatial diversification of spinal motor neurons.

Authors:  Geok Soon Lim; Jin Hui Hor; Nicholas R Y Ho; Chi Yan Wong; Shi Yan Ng; Boon Seng Soh; Huilin Shao
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

Review 6.  A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?

Authors:  Xiaojiao Xu; Dingding Shen; Yining Gao; Qinming Zhou; You Ni; Huanyu Meng; Hongqin Shi; Weidong Le; Shengdi Chen; Sheng Chen
Journal:  Transl Neurodegener       Date:  2021-08-10       Impact factor: 8.014

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.